Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The utilization of arthroscopic surgery to treat meniscus injuries has continued to increase
in recent years, partly due to a younger, more active population, and improved technology and
technique. However, pain management in the post-operative period is critical to the ability
to perform this procedure as an outpatient surgery. Traditionally, oral narcotic agents have
been the preferred analgesic postoperatively in orthopaedic surgery. However, these agents
are associated with several side effects, including nausea/vomiting, constipation, and
somnolence. In addition, opioid agents have a significant potential for abuse in comparison
to non-narcotic analgesics. In light of the rising opioid epidemic and nationwide initiatives
to limit narcotic usage, surgeons must explore alternate pain modalities in the acute
postoperative period. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) with
analgesic and anti-inflammatory properties.1 Multiple prior studies have examined the
beneficial effect of oral and intravenous (IV) ketorolac as an analgesic in the postoperative
period,1-3 including arthroscopic meniscus surgery. However, the beneficial effects of this
agent following arthroscopic meniscus surgery have not been extensively described.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospitals Cleveland Medical Center
Treatments:
Acetaminophen Acetaminophen, hydrocodone drug combination Ketorolac Ketorolac Tromethamine Oxycodone